Clinical Study of Entecavir Combined with Chemotherapy in the Treatment of Positive HBV in Tumor Pa-tients with Normal Liver Function / 中国药房
China Pharmacy
;
(12): 4983-4984,4985, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-605886
ABSTRACT
OBJECTIVE:
To explore the effects of entecavir combined with chemotherapy on positive HBV in tumor patients with normal liver function.METHODS:
106 patients were selected and divided into observation group (44 cases) and control group (62 cases) according to therapy plan. Control group received routine chemotherapy according to tumor condition;observa-tion group was given Entecavir tablets orally 0.5 mg,qd,before 1 week of chemotherapy,for consecutive 1 week. HBV reactiva-tion rate,recurrence rate of severe hepatitis,mortality rate,serum level of ALT before and after treatment and the incidence of ADR were compared between 2 groups.RESULTS:
4 patients of observation group and 2 of control group withdrew from the study. HBV reactivation rate,recurrence rate of severe hepatitis and mortality were 7.5%,0,0 in observation group and 56.7%, 50.0%,13.3% in control group,with statistical significance between 2 groups(P0.05);after chemotherapy,the serum levels of ALT in 2 groups were increased significantly,and the control group was significantly higher than the observation group,with statistical significance (P0.05).CONCLUSIONS:
Entecavir can effectively prevent HBV reactivation and decrease the recurrence rate of severe hepatitis and mortality rate in tumor patients dur-ing chemotherapy, and doesn’t increase the risk of ADR.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
China Pharmacy
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS